Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 27Fluorouracil 23Leucovorin 22Cetuximab 22Bevacizumab 21Nivolumab 16Capecitabine 16Irinotecan 15pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10encorafenib 8Folfox protocol 7trifluridine tipiracil drug combination 6Ipilimumab 6Exercise 6fludarabine 5cemiplimab 5Trastuzumab 5Gemcitabine 5Cyclophosphamide 5Cisplatin 5Blood Specimen Collection 5Biopsy 5regorafenib 4pertuzumab 4adagrasib 4Trifluridine 4Pemetrexed 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × NP-G2-044 × 1 year × Clear all
NCT03199586 2025-07-20

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

Phase 1 Completed
23 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡